Lungs Heart The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes. Full results from the phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback